Dawn A Laney1, Dawn S Peck2, Andrea M Atherton3, Linda P Manwaring4, Katherine M Christensen5, Suma P Shankar1, Dorothy K Grange4, William R Wilcox1, Robert J Hopkin6. 1. Division of Medical Genetics, Department of Human Genetics, Decatur, Georgia, USA. 2. Division of Medical Genetics, University of Missouri Children's Hospital, University of Missouri Health System, Columbia, Missouri, USA. 3. Section of Genetics, Children's Mercy Hospitals, Kansas City, Missouri, USA. 4. Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, Missouri, USA. 5. Division of Medical Genetics, SSM Cardinal Glennon Children's Medical Center, St. Louis, Missouri, USA. 6. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Missouri, USA.
Abstract
PURPOSE: Fabry disease is a pan-ethnic, progressive, X-linked genetic disorder that commonly presents in childhood and is caused by deficient activity of the lysosomal enzyme alpha-galactosidaseA (α-gal A). Symptoms of Fabry disease in the pediatric population are well described for patients over five years of age; however, data are limited for infancy and early childhood. The purpose of this article is to delineate the age of detection for specific Fabry symptoms in early childhood. METHODS: A systematic retrospective analysis of PubMed indexed, peer-reviewed publications and case reports in the pediatric Fabry population was performed to review symptoms in patients reported before 5 years of age. RESULTS: The most frequently reported symptom in all age groups under 5 years was acroparesthesias/neuropathic pain, reported in 9 children, ranging in age from 2.0-4.0 years. Also notable is the frequency of gastrointestinal issues reported in 6 children aged 1.0-4.1 years of age. CONCLUSION: This article finds clear evidence that symptoms can occur in early childhood, before age 5 years. Given early presenting symptoms and the ability to monitor these disease hallmarks, a timely referral to a medical geneticist or other specialty clinician experienced in managing children with Fabry disease is strongly indicated.
PURPOSE: Fabry disease is a pan-ethnic, progressive, X-linked genetic disorder that commonly presents in childhood and is caused by deficient activity of the lysosomal enzyme alpha-galactosidaseA (α-gal A). Symptoms of Fabry disease in the pediatric population are well described for patients over five years of age; however, data are limited for infancy and early childhood. The purpose of this article is to delineate the age of detection for specific Fabry symptoms in early childhood. METHODS: A systematic retrospective analysis of PubMed indexed, peer-reviewed publications and case reports in the pediatric Fabry population was performed to review symptoms in patients reported before 5 years of age. RESULTS: The most frequently reported symptom in all age groups under 5 years was acroparesthesias/neuropathic pain, reported in 9 children, ranging in age from 2.0-4.0 years. Also notable is the frequency of gastrointestinal issues reported in 6 children aged 1.0-4.1 years of age. CONCLUSION: This article finds clear evidence that symptoms can occur in early childhood, before age 5 years. Given early presenting symptoms and the ability to monitor these disease hallmarks, a timely referral to a medical geneticist or other specialty clinician experienced in managing children with Fabry disease is strongly indicated.
Authors: Markus Ries; Surya Gupta; David F Moore; Vandana Sachdev; Jane M Quirk; Gary J Murray; Douglas R Rosing; Chevalia Robinson; Ellen Schaefer; Andreas Gal; James M Dambrosia; Scott C Garman; Roscoe O Brady; Raphael Schiffmann Journal: Pediatrics Date: 2005-02-15 Impact factor: 7.124
Authors: U Ramaswami; S Wendt; G Pintos-Morell; R Parini; C Whybra; J A Leon Leal; F Santus; M Beck Journal: Acta Paediatr Date: 2007-01 Impact factor: 2.299
Authors: O Lidove; P Kaminsky; E Hachulla; V Leguy-Seguin; C Lavigne; I Marie; F Maillot; C Serratrice; A Masseau; P Chérin; J Cabane; E Noel Journal: Clin Genet Date: 2011-06-21 Impact factor: 4.438
Authors: Markus Ries; Joe T R Clarke; Catharina Whybra; Margaret Timmons; Chevalia Robinson; Bradley L Schlaggar; Gregory Pastores; Y Howard Lien; Christoph Kampmann; Roscoe O Brady; Michael Beck; Raphael Schiffmann Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: Christoph Kampmann; Christiane M Wiethoff; Catharina Whybra; Frank A Baehner; Eugen Mengel; Michael Beck Journal: Acta Paediatr Date: 2008-04 Impact factor: 2.299
Authors: Dawn A Laney; Virginia Clarke; Allison Foley; Eric W Hall; Scott E Gillespie; Myrl Holida; Morgan Simmons; Alexandrea Wadley Journal: JIMD Rep Date: 2017-03-22